Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
株式のランク
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
株価
$6.17
時価総額
$3.52B
変化（1日）
-0.05%
変化（1年）
-1.86%
国
CN
取引 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
カテゴリー
Healthcare
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited（600329）のP/E比率
October 2026 時点のP/E比率 TTM 37.37
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 37.37 です。2024 年末時点での P/E は 10.64 でした。
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited の P/E 比率の履歴（2001 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 37.37 | 126.89% |
| 2025 | 16.47 | 54.78% |
| 2024 | 10.64 | -59.53% |
| 2023 | 26.29 | 1.26% |
| 2022 | 25.96 | -17.31% |
| 2021 | 31.40 | 54.24% |
| 2020 | 20.36 | 19.50% |
| 2019 | 17.04 | 4.75% |
| 2018 | 16.26 | -32.78% |
| 2017 | 24.19 | -23.66% |
| 2016 | 31.69 | -10.14% |
| 2015 | 35.27 | 10.93% |
| 2014 | 31.79 | 20.92% |
| 2013 | 26.29 | 48.82% |
| 2012 | 17.67 | -37.71% |
| 2011 | 28.36 | -22.02% |
| 2010 | 36.38 | 17.88% |
| 2009 | 30.86 | 65.68% |
| 2008 | 18.63 | -130.45% |
| 2007 | -61.16 | 1,134.91% |
| 2006 | -4.95 | -127.87% |
| 2005 | 17.77 | -39.63% |
| 2004 | 29.44 | 10.44% |
| 2003 | 26.66 | -36.86% |
| 2002 | 42.22 | -45.27% |
| 2001 | 77.13 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 55.58 | 48.72% |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -6.45% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。